Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | METAP1 | P53582 | 3/20 | 0.36 |
| ▸ | CAD | P27708 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6846658 | 1.00 | ALOX15 (0.42) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL135322 | 0.95 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6389387 | 0.95 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL196141 | 0.95 | ALOX15 (0.46) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL6389383 | 0.93 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL135321 | 0.93 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3918851 | 0.93 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL138333 | 0.93 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3918852 | 0.93 | ALOX15 (0.44) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8758723 | 0.85 | ALOX15 (0.38) | ALOX15SLC7A5ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304516-B | Compounds with unconventional chromophores, their preparation and use | 四川大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-110248946-B | Azepan inhibitors of the Menin-MLL interaction | 詹森药业有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-20 | — | — | US | disclosed |
| CN-115304516-A | Compounds with unconventional chromophores, their preparation and use | 四川大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-3555103-B1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-29 | — | — | US | disclosed |
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-18 | — | — | US | disclosed |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| EP-3555103-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109088-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745409-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | ALOX15 2407/4885SLC7A5 4174/4885ALDH1A1 3880/4885 |
| US-20190322685-A1 | AZEPANE INHIBITORS OF MENIN-MLL INTERACTION | MEN1, MLLT1, BMI1 | ALOX15 2407/4885SLC7A5 4174/4885ALDH1A1 3880/4885 |
| US-11530226-B2 | Azepane inhibitors of menin-MLL interaction | MEN1, MLLT1, BMI1 | ALOX15 2407/4885SLC7A5 4174/4885ALDH1A1 3880/4885 |
| US-20200339594-A1 | Azepane Inhibitors Of Menin-MLL Interaction | MEN1, MLLT1, BMI1 | ALOX15 2407/4885SLC7A5 4174/4885ALDH1A1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.